Actelion welcomes interest in becoming a stockholder in the company. This area provides information on how to buy Actelion stock, as well as some explanations of the terminology commonly used in describing Actelion’s finances and the stock market in general. It also provides answers to frequently asked questions (FAQs) about Actelion’s foundation and stock listings.
The most important question it answers is why Actelion is a good investment.
A patient oriented approach supported by a culture focused on innovation, trust and teamwork enables Actelion to flourish in the biopharmaceutical sector through retaining and attracting the best people in the industry. By making pulmonary arterial hypertension (PAH) a recognized and treatable disease, Actelion has improved the lives of thousands of patients.
In addition, Actelion has developed not only a world-wide marketing infrastructure, but also the drug discovery and clinical development capability to reproduce this innovation in other areas of high unmet medical need.
Actelion will continue to bring innovative medicines to patients.
Actelion is preparing for transformational growth, putting processes and infrastructure in place that will allow its novel chemical entities currently in late stage development to become innovative medicines for patients in areas of high unmet medical need.
Execution of our growth strategy is possible due to a focus on innovation, entrepreneurial spirit, an enthusiastic work environment, and a strong financial performance.
Actelion’s core strategic focus is on further expanding its clinical pipeline with development candidates from in-house research, but it is also open to innovation from third parties.
It is this strategy which enables Actelion to remain at the forefront of the biopharmaceutical sector, creating and maximizing the value of innovation to benefit all stakeholders.